| MR编号 | DE/V/0251/001 |
|---|
| 药品名称 | Versican DHPPi/L3R |
|---|
| 活性成分 | - canine adenovirus 4.9 GKID50
- canine distemper virus 4.7 GKID50
- canine parainfluenza virus 4.6 GKID50
- canine parvovirus 6.1 GKID50
- leptospira interrogans serogroup canicola 32.0 MALR
- leptospira interrogans serogroup icterohaemorragiae 32.0 MALR
- Rabies virus, inactivated 2.0 IU
|
|---|
| 剂型 | Suspension for injection |
|---|
| 上市许可持有人 | Pfizer Ltd.
Ramsgate Road
Sandwich, Kent, CT13 9NJ
UK |
|---|
| 参考成员国 - 产品名称 | Germany (DE) Versican DHPPi/L3R |
|---|
| 互认成员国 - 产品名称 | - Cyprus (CY)
- Belgium (BE)
VERSICAN DHPPI/L3R - Luxembourg (LU)
- France (FR)
VERSICAN DHPPI/L3R LYOPHILISAT ET SOLVANT POUR SUSPENSION INJECTABLE POUR CHIENS - Spain (ES)
VERSICAN DHPPi/L3R - Portugal (PT)
- Latvia (LV)
- Lithuania (LT)
Versican DHPPi/L3R, liofilizatas ir skiediklis injekcinei suspensijai šunims - Hungary (HU)
- Czechia (CZ)
- Slovakia (SK)
- Greece (GR)
- Poland (PL)
|
|---|
| 许可日期 | 2011/12/21 |
|---|
| 最近更新日期 | 2017/05/26 |
|---|
| 药物ATC编码 | - QI07AJ06 live canine distemper virus + live canine adenovirus + live parainfluenza virus + live canine parvovirus + inactivated rabies + inactivated leptospira
| 申请类型 | - TypeLevel1：[not specified]
- TypeLevel2：[not specified]
- TypeLevel3：Full dossier - art 12.3 Dir 2001/82/EC
- TypeLevel4：[not specified]
- TypeLevel5：[not specified]
|
|---|
| 附件文件下载 | |
|---|
| 市场状态 | Positive |
|---|
|
|---|